Jasmin Tiro to Retrospective Studies
This is a "connection" page, showing publications Jasmin Tiro has written about Retrospective Studies.
Connection Strength
0.340
-
Barriers to the Equitable Implementation of Risk-Based Cervical Cancer Management Guidelines. J Gen Intern Med. 2026 Feb; 41(3):759-766.
Score: 0.083
-
Cervical cancer screening among HIV-infected women in an urban, United States safety-net healthcare system. AIDS. 2018 08 24; 32(13):1861-1870.
Score: 0.052
-
Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-based Integrated Health Care Delivery System. J Clin Gastroenterol. 2017 Aug; 51(7):650-655.
Score: 0.048
-
Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila). 2012 Sep; 5(9):1124-30.
Score: 0.034
-
Gaps in care across the cancer screening continuum for cervical, colorectal, and lung cancers. J Natl Cancer Inst. 2025 Dec 01; 117(12):2556-2570.
Score: 0.021
-
Guideline-Concordant Surveillance After Treatment for High-Grade Cervical Dysplasia. Obstet Gynecol. 2025 May 01; 145(5):461-468.
Score: 0.020
-
Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2020 08; 52(4):701-709.
Score: 0.015
-
Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States. Am J Gastroenterol. 2018 05; 113(5):746-754.
Score: 0.013
-
Primary care visit use after positive fecal immunochemical test for colorectal cancer screening. Cancer. 2017 Oct 01; 123(19):3744-3753.
Score: 0.012
-
An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology. 2017 04; 65(4):1196-1205.
Score: 0.012
-
Reasons for Lack of Diagnostic Colonoscopy After Positive Result on Fecal Immunochemical Test in a Safety-Net Health System. Am J Med. 2017 Jan; 130(1):93.e1-93.e7.
Score: 0.011
-
Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med. 2015 Jan; 128(1):90.e1-7.
Score: 0.010
-
Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma. J Natl Compr Canc Netw. 2013 Sep 01; 11(9):1101-8.
Score: 0.009